Specific primer for detecting residual DNA (Deoxyribose Nucleic Acid) of escherichia coli in biological product
By designing specific primers and real-time fluorescence quantitative nucleic acid amplification reaction system, the problem of insufficient specificity and sensitivity of E. coli residual DNA detection in the prior art is solved, and efficient and accurate E. coli residual DNA in biological products is achieved. Testing meets the limit requirements of drug supervision and administration agencies.
Patent Information
- Application Number
- CN202411397072.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-08
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art has shortcomings in detecting the specificity, sensitivity and accuracy of E. coli residual DNA in biological products, and it is difficult to meet the strict requirements of drug regulatory agencies on the limits of residual DNA.
Design and screen out specific primers, combine real-time fluorescence quantitative nucleic acid amplification reaction system, and detect them through extraction kits and specific primers to achieve efficient and rapid detection of E. coli residual DNA.
It provides a sensitive, accurate and robust detection method that can efficiently distinguish other host cells, with a detection capability of nearly 1,000 times higher than that of the commercial kit, and the detection results are accurate, and are suitable for quantitative detection of residual DNA in recombinant hepatitis E vaccine.
Smart Images

Figure CN119040493A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biological detection, and particularly relates to a specific primer for detecting residual DNA of Escherichia coli in biological products. Background Art
[0002] Due to the advancement of genetic engineering technology, Escherichia coli expression system is widely used in the expression and production of recombinant proteins due to its easy genetic manipulation, well-characterized genome, available multi-purpose plasmid vectors, adaptability to different host strains, cost-effectiveness and high expression level of the desired protein.
[0003] Since residual DNA of E. coli host cells may appear in biological products, these residual DNA fragments of host cells may transmit tumor or virus-related genes, which is potentially dangerous. Drug regulatory agencies in various countries have strict limit control on the residual amount of host cell DNA and the standards are constantly improving: 1. In 1987, WHO proposed that the standard for residual DNA in non-oral biological products is ≤100pg / dose. 2. In 1998, WHO revised the standard for residual DNA in non-oral biological products to ≤10ng / dose through risk assessment. 3. In 1984, FDA recommended that the acceptable limit of residual DNA is ≤10ng / dose. 4. In 1997, FDA revised the standard to ≤100pg / dose. 5. In 2019, the limit for residual DNA in the European Pharmacopoeia General Rules is ≤10ng / dose, but some vaccines are different. 6. In 2010, the third volume of the Pharmacopoeia of the People's Republic of China requires that the residual DNA of therapeutic genetic engineering recombinant products expressed by E. coli is ≤10ng / dose.
[0004] Therefore, establishing a suitable detection method for residual DNA in the E. coli expression system is crucial to monitoring the safety and quality controllability of biological products. In the past few decades, threshold method, hybridization method and real-time quantitative PCR have been reported, but traditional detection methods still need to be improved in terms of specificity, sensitivity, accuracy and detection stability. Summary of the invention
[0005] In view of the shortcomings of the prior art, the present invention designs and synthesizes a specific primer for detecting residual DNA of Escherichia coli in biological products by screening gene fragments of E. coli, evaluates the quality of the primer and determines its detection ability by using relevant software and tools, extracts the residual DNA in the recombinant hepatitis E vaccine stock solution by using a commercial extraction kit, and then uses an amplification system established based on the designed primers for detection. It has been methodologically verified that the method is a sensitive, accurate and robust detection method, which can be used for the efficient and rapid detection of the residual DNA content of Escherichia coli in the Escherichia coli expression system.
[0006] The technical solution of the present invention is:
[0007] The first aspect of the present invention provides a specific primer for detecting the residual DNA content of Escherichia coli in biological products, comprising a forward primer and a reverse primer having nucleotide sequences as shown in SEQ ID NO.1-2.
[0008] The second aspect of the present invention provides the use of the aforementioned specific primers in the preparation of a detection product for the residual DNA content of Escherichia coli in biological products.
[0009] The third aspect of the present invention provides a real-time fluorescent quantitative nucleic acid amplification detection kit for detecting the residual DNA content of Escherichia coli in biological products, which comprises a real-time fluorescent quantitative nucleic acid amplification reaction system, and the real-time fluorescent quantitative nucleic acid amplification reaction system contains the aforementioned specific primers.
[0010] In some embodiments, the real-time fluorescent quantitative nucleic acid amplification reaction system is 25 μL, including 0.5 μL of forward primer and 0.5 μL of reverse primer.
[0011] In some embodiments, the real-time fluorescent quantitative nucleic acid amplification reaction system further comprises a reaction buffer, dNTPs, Taq DNA polymerase and template DNA.
[0012] In some embodiments, the real-time fluorescent quantitative nucleic acid amplification reaction system is 25 μL and contains the following components: 12.5 μL SsoFastTM Supermix, 0.5 μL forward primer, 0.5 μL reverse primer, 10 μL template DNA, 1.5 μL water.
[0013] The fourth aspect of the present invention provides the use of the aforementioned kit in detecting the residual DNA content of Escherichia coli in biological products for purposes other than disease diagnosis or treatment.
[0014] In some embodiments, the biologic is a vaccine produced by an E. coli expression system.
[0015] The fifth aspect of the present invention provides a method for detecting the content of Escherichia coli DNA in biological products, comprising: extracting DNA from a sample to be tested; using the extracted DNA as a template and employing the aforementioned specific primers or kit to perform real-time fluorescent quantitative nucleic acid amplification detection.
[0016] In some embodiments, the program of real-time fluorescent quantitative nucleic acid amplification includes: 98°C for 3 min; 35-40 cycles: 98°C for 15 s, 55°C for 1 min.
[0017] The beneficial effects of the present invention are:
[0018] The specific primers provided by the present invention can be used for efficient and rapid detection of the residual DNA content of Escherichia coli in the Escherichia coli expression system, and can effectively distinguish other hosts, such as yeast cells, CHO cells, etc. The detection ability is nearly 1000 times higher than that of commercial kits, and has the characteristics of good specificity, high sensitivity and high accuracy of detection results.
[0019] The detection method provided by the present invention has been methodologically verified to be a sensitive, accurate and robust detection method, which can more accurately quantify the residual DNA content in the recombinant hepatitis E vaccine in production practice. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The results are validated specifically for E. coli;
[0021] Figure 2 is the E.coli standard curve;
[0022] Figure 3 This is the linearity verification result of E.coli. DETAILED DESCRIPTION
[0023] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention is clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0024] Materials in the following examples: E. coli Host Cell DNA Extraction﹠Amplification Kitin Tubes were purchased from CYGNUS TECHNOLOGIES, iQ TM Green Supermix and SsoFast TM Supermix was purchased from BIO-RAD, USA.
[0025] Example 1 Design and screening of primers for residual DNA detection in E. coli expression system
[0026] The 16S rRNA sequence of the E. coli genome was selected, and primers were designed using the online tool PrimerQuest from Integrated DNA Technologies, followed by quality evaluation using the software Oligo 7.0. Finally, primer pairs with higher amplification efficiency were screened out according to the annealing temperature optimization results. The screened primer pairs have forward primers and reverse primers shown in SEQ ID NO: 1-2, as shown in Table 1.
[0027] Table 1 Primer pair sequences
[0028] Primer name SEQ ID NO sequence Forward primer 1 GGCCTTCGGGTTGTAAAG Reverse primer 2 GTTAGCCGGTGCTTCTTC
[0029] Example 2 Application of the primers of the present invention to detect residual DNA of Escherichia coli in biological products
[0030] Use E.coli Host Cell DNA Extraction Kit to extract residual DNA in the recombinant hepatitis E vaccine stock solution. The steps are as follows: take 150μL of the recombinant hepatitis E vaccine stock solution, and dilute the sample to be tested with the sample diluent at a ratio of 1:2; add 25μL of diluted proteinase K to each tube and shake gently for 5 seconds; in a 60℃ water bath or metal bath for 50-70min; take out and collect the liquid on the lid and tube wall at 10000rpm for 30 seconds; add 450μL DNA Extraction Buffer to each tube, shake for 5 seconds, and mix well; add 1mL DNA Precipitation Buffer, shake for 5 seconds, and let stand for 5min; 10000rpm for 10min; discard the supernatant, invert, and let the liquid drain; add 1.5mL DNA Wash Buffer to each tube, shake for 5 seconds, and let stand for 20min (shake 1-2 times during the period); 10000rpm5min; discard the supernatant, invert, and let the liquid drain; add 250μL 50℃ preheated TE to each tube Buffer, shake for 5 seconds, and let stand for 5 minutes to obtain the sample residual DNA purification solution.
[0031] After the residual DNA in the recombinant hepatitis E vaccine stock solution was extracted using the E.coli Host Cell DNA Extraction Kit, the primers of the present invention and the E.coli Host Cell DNA Amplification Kit were used to perform qPCR experiments, respectively, to compare their detection amounts. After the detection was performed using the E.coli Host Cell DNA Extraction Kit and the primer pair of the present invention (matched with the corresponding amplification reagent) and the detection concentration was standardized according to the recovery rate, the detection amounts of the commercial kit and the primers of the present invention were 0.007pg / dose and 8.132pg / dose, respectively (Table 2). By comparison, it can be seen that the detection amount of the primers of the present invention is significantly higher than that of the commercial kit.
[0032] Table 2 Comparison of residual DNA detection in Ecoli
[0033]
[0034] The commercial E. coli kit and the amplification system of the method of the present invention are shown in Table 3.
[0035] Table 3 Comparison of different amplification systems of E. coli
[0036]
[0037] Among them, ST1 / ST2 / ST3 / ST4 / ST5 / ST6 are standard samples, NCS extract is the sample to be tested after negative control treatment, and spiked sample extract is the sample to be tested after spiked sample treatment.
[0038] Example 3 Methodological verification of the primers of the present invention for detecting residual DNA of Escherichia coli in biological products
[0039] According to the ICH (International Conference on Harmonization) guidelines, the method of detecting residual DNA of Escherichia coli in biological products by using the primers of the present invention was validated in terms of specificity, sensitivity (limit of detection, LOD), limit of quantification (LOQ), accuracy, precision and linearity. The acceptance criteria were: spike recovery rate 50%-150%, intra-assay precision ≤5%, intermediate precision ≤10%, standard curve R 2 ≥0.98. The results are as follows:
[0040] 1. Establishment of standard curve
[0041] After extracting E. coli genomic DNA using a genomic DNA extraction kit according to the instructions, the A 260 / A 280DNA was quantified. Six concentrations of 10-fold serial dilution were used to establish a standard curve. Specifically, E. coli genomic DNA was diluted 10-fold (10+90) with TE buffer to 100 pg / μL, 10 pg / μL, 1 pg / μL, 100 fg / μL, 10 fg / μL, and 1 fg / μL to establish a standard curve.
[0042] 2. Specificity
[0043] By BLAST analysis, the amplicon of the EA2 primer pair had no duplication with other genomic sequences. Subsequently, the primers of the present invention were used to detect the genomic DNA of E. coli, CHO, yeast, human, Vero cells, mice, respiratory syncytial virus (RSV) and rabies virus (RV). The results are as follows Figure 1 As shown in the figure, it can be seen that the primer pair of the present invention does not amplify other unrelated genomes, and only the E. coli gene shows an amplification curve, indicating good specificity.
[0044] 3. Limit of detection and limit of quantification
[0045] The LOD (limit of detection) was determined by establishing a standard curve. The standard curve range was 1fg / μL-1×10 6 fg / μL, each standard was tested in triplicate, and all concentrations showed amplification curves within 40 cycles, e.g. Figure 2 As shown. 10pg, 1pg and 0.1pg E.coli DNA standards were added to the recombinant hepatitis E vaccine stock samples, extracted by the established universal sample pretreatment method - coprecipitation method, and then qPCR was performed. Observe whether samples with known DNA concentrations can be accurately measured with appropriate recovery rates to determine the LOQ (limit of quantification). The experimental results showed that the LOD and LOQ of this study were 1fg / μL and 1pg / reaction, respectively (Table 4).
[0046] Table 4 Determination of quantification limit of E. coli
[0047]
[0048]
[0049] 4. Precision
[0050] The intra-assay precision was determined from the results of a single experiment, and the standard deviation (SD) and coefficient of variation (CV) of the CT value for each concentration were 0.029-0.165 and 0.131%-0.519%, respectively (Table 5). The intermediate precision was determined based on the experimental results in three different experiments on three different dates. The SD and CV were 0.300-0.780 and 1.377%-2.372%, respectively (Table 6).
[0051] Table 5 Intra-batch precision of E. coli
[0052]
[0053] Table 6 E.coli intermediate precision
[0054]
[0055] 5. Accuracy
[0056] Three different concentrations (10000pg / mL, 1000pg / mL, 100pg / mL) of test samples were obtained by adding different amounts of E. coli standard DNA to the recombinant hepatitis E vaccine stock solution. The samples and spiked samples were processed by the self-established sample pretreatment method, and then the qPCR experiment was repeated 9 times on different days. The accuracy was then evaluated by calculating the recovery rate. The average recovery rate was 56.7%-83.9% (Table 7). These results show that the method has good accuracy and also indicate that the optimized sample pretreatment method has good extraction efficiency.
[0057] Table 7 E.coli accuracy verification
[0058]
[0059] 6. Linear
[0060] Linearity was evaluated by calculating the R2 value of multiple standard curves. Three standard curves were drawn by plotting the average CT versus DNA concentration. Three standard curves were obtained from three independent experiments performed on different days. The R2 values of the three standard curves all satisfied R2 ≥ 0.98. Figure 3 As shown, it shows that the linearity meets the requirements.
[0061] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
Claims
1. A specific primer for detecting the residual DNA content of Escherichia coli in biological products, characterized in that: The specific primers include a forward primer and a reverse primer whose nucleotide sequences are shown as SEQ ID NO. 1-2.
2. Use of the specific primers described in claim 1 in preparing a product for detecting the residual DNA content of Escherichia coli in biological products.
3. A real-time fluorescent quantitative nucleic acid amplification detection kit for detecting the residual DNA content of Escherichia coli in biological products, characterized in that: The kit comprises a real-time fluorescent quantitative nucleic acid amplification reaction system, and the real-time fluorescent quantitative nucleic acid amplification reaction system contains the specific primers according to claim 1.
4. The kit according to claim 3, characterized in that The real-time fluorescent quantitative nucleic acid amplification reaction system is 25 μL, including 0.5 μL of forward primer and 0.5 μL of reverse primer.
5. The kit according to claim 3 or 4, characterized in that The real-time fluorescent quantitative nucleic acid amplification reaction system also includes a reaction buffer, dNTPs, Taq DNA polymerase and template DNA.
6. The kit according to claim 5, characterized in that The real-time fluorescence quantitative nucleic acid amplification reaction system contains the following components in 25 μL: 12.5 μL SsoFastTM Supermix, 0.5 μL forward primer, 0.5 μL reverse primer, 10 μL template DNA, 1.5 μL water.
7. Use of the specific primers according to claim 1 or the kit according to any one of claims 3 to 6 in detecting the residual DNA content of Escherichia coli in biological products for purposes other than disease diagnosis or treatment.
8. The use according to claim 7, characterized in that: The biological product is a vaccine produced by an Escherichia coli expression system.
9. A method for detecting the content of Escherichia coli DNA in biological products, characterized in that: The method comprises: Extracting DNA from the sample to be tested; The extracted DNA is used as a template and the specific primers described in claim 1 or the kit described in any one of claims 3 to 6 are used to perform real-time fluorescent quantitative nucleic acid amplification detection.
10. The method according to claim 9, characterized in that The program of the real-time fluorescent quantitative nucleic acid amplification includes: 98° C. for 3 min; 35-40 cycles: 98° C. for 15 s, 55° C. for 1 min.
